Explore the Agenda
8:00 am Morning Coffee and Check-In
Workshop A
9:00 am Supercharging T-Cell Engager Efficacy with Co-Stimulation: Formats, Targets & Strategies to Achieve Durable Responses with Improved Potency & Optimized Safety
As T cell engagers push into solid tumours and earlier-line settings, co-stimulation has emerged as one of the most promising levers for boosting efficacy and durability. This high-impact strategy workshop brings together pioneering T-cell engager experts to tackle which co-stimulatory receptor to target, how to time activation signals, and whether to build into a single trispecific or deliver sequentially. You’ll gain practical, actionable insights on overcoming tumour microenvironment barriers, managing exhaustion, and minimising safety risks. If you’re serious about engineering next-generation TCEs that deliver longlasting responses, this is the must-attend session to get ahead of the curve.
This workshop will cover:
- Clarifying the biological rationale – How co-stimulatory domains (CD28, CD137, CD2 etc.) enhance T cell fitness, prevent early exhaustion, and improve anti-tumour activity and aligning primary CD3 activation with co-stimulation signals to maximise efficacy and avoid mismatched signalling
- Choosing the right co-stimulatory target – Comparative advantages, limitations, and clinical unknowns for different T-cell engager targets
- Design and delivery strategies – How linking co-stimulatory elements directly to the engager can optimise timing, localisation, and therapeutic effect
- Managing exhaustion and safety risks – Avoiding on-target/off-tumour risks by activation of non tumour T cell subsets, reducing CRS, and limiting Fc-mediated toxicity
- Combinations vs trispecifics – Comparing strategies, advantages, and limitations – looking at clinical data
12:00 pm Lunch Break
Workshop B
1:00 pm Translating Co-Stimulation from Bench to Bedside: Lessons from Haematology & Strategies to Unlock Solid Tumour Responses
This workshop offers a uniquely data-driven and translational perspective on co-stimulation. Drawing on clinical-stage learnings from haematologic indications, unpack how co-stimulation behaves in real patients, how early preclinical signals map to later clinical outcomes, and how these insights can critically inform the strategic design and next steps for T-cell engagers targeting solid tumors.
This workshop will cover:
- What Clinical Data Tells Us: Key findings from Roche’s haematology programs: how co-stimulatory domains improved efficacy, durability, and T-cell fitness in the clinic
- Bridging Preclinical → Clinical: How different domains signal in preclinical models, which readouts most reliably predict clinical behaviour, and which don’t
- Co-Stimulation in Solid Tumours: Why success in the haem space hasn’t yet translated to solid tumours, and what biological & microenvironmental barriers must be engineered around
- Domain & Biology Optimization: Comparative assessment of co-stimulatory signals (e.g., CD28 vs CD137) and how their biology may inform domain prioritisation specifically for solid tumour contexts
- Strategic Design Framework: Leveraging clinical learnings and key assumptions to define the strategic and next-step approaches for solid tumour co-stimulation design.